Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,009.52 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EST, Feb 20, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
Eli Lilly Announces New Version Of Zepbound With A Month’s Worth Of Doses In KwikPen — How Much Will It Cost? ↗
The new Zepbound KwikPen can be purchased by cash-paying customers through LillyDirect, Eli Lilly’s direct-to-customer website. 
Via Stocktwits
Wondering what's happening in today's S&P500 pre-market session? ↗
Via Chartmill
News headline image
Novo Nordisk Dives As Next-Gen Obesity Drug Fails To Match Eli Lilly's Zepbound ↗
Novo's next-gen drug CagriSema didn't match weight loss from Eli Lilly's Zepbound. 
Via Investor's Business Daily
News headline image
1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock ↗
Novo Nordisk investors get a second bite at the Ozempic apple. 
Via The Motley Fool
News headline image
3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗
Viking stock has plenty of room to run. 
Via The Motley Fool
News headline image
Corcept (CORT) Q4 Earnings: What To Expect
Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Tuesday afternoon. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence World Trade
News headline image
Jazz Pharmaceuticals Earnings: What To Look For From JAZZ
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be announcing earnings results this Tuesday after market close. Here’s what you need to know. 
Via StockStory
Topics Artificial Intelligence Government World Trade
News headline image
Supernus Pharmaceuticals (SUPN) To Report Earnings Tomorrow: Here Is What To Expect
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Tuesday after market hours. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
News headline image
What To Expect From Elanco’s (ELAN) Q4 Earnings
Animal health company Elanco (NYSE:ELAN) will be reporting earnings this Tuesday before market open. Here’s what you need to know. 
Via StockStory
News headline image
Could Vertex Stock Help Turn $100,000 Into $1 Million by 2036? ↗
Even a great stock has a ceiling. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200 ↗
These two healthcare stocks are likely headed higher from their current prices. 
Via The Motley Fool
News headline image
3 Brilliant Growth Stock ETFs to Buy Now and Hold for the Long Term ↗
Growth stock ETFs offer a catch-all way to buy the dip in top stocks. 
Via The Motley Fool
Topics Artificial Intelligence ETFs
News headline image
The Stock Market Just Did This for the First Time in Nearly a Year. History is Strikingly Clear About What Happens Next. ↗
Market gains have left some stocks trading at expensive levels. 
Via The Motley Fool
Topics Artificial Intelligence Economy
News headline image
Novo Nordisk Stock Investors Just Got Great News From Eli Lilly ↗
But it's good news for Eli Lilly, too. 
Via The Motley Fool
News headline image
Is Pfizer Stock an Underrated Healthcare Investment Play? ↗
Pfizer is playing catch-up in the GLP-1 drug space, but the drugmaker has a long history of success. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins ↗
Wall Street is overly focused on GLP-1 drugs even as this medical device maker continues to thrive. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Breaks New Ground In Crohn's Disease Treatment ↗
Eli Lilly (LLY) reports landmark Phase 3 data for Omvoh, showing over 90% of Crohn's disease patients achieved 3-year steroid-free remission. 
Via Benzinga
News headline image
Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗
New products are already generating growth. 
Via The Motley Fool
Topics Intellectual Property
News headline image
ORBIMED Advisors Trims $125 Million Terns Stake After a Breakout Year, According to SEC Filing ↗
Terns Pharmaceuticals has delivered a significant rally over the past year, lifting expectations around its clinical pipeline. The latest filing shifts attention to upcoming data and the company’s... 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
3 Market-Beating Stocks to Consider Right Now
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three for years on end are almost always the... 
Via StockStory
News headline image
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗
These biotech companies have catalysts ahead. 
Via The Motley Fool
News headline image
Warning: This Skyrocketing Stock Has a Hidden Risk ↗
Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever. 
Via The Motley Fool
Topics Intellectual Property
News headline image
Prediction: Eli Lilly Stock Could Surge 45% This Year ↗
Eli Lilly just delivered explosive growth, and analysts see up to 45% upside, but is this pharma giant still a buy at its current price? 
Via The Motley Fool
News headline image
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention ↗
Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year. 
Via The Motley Fool
News headline image
Is Viking Therapeutics Stock Really Going to $125? ↗
Never say never. There's certainly a mathematical path to that level, if the company navigates it correctly. 
Via The Motley Fool
News headline image
3 Stocks to Buy and Hold for 2026 and Beyond ↗
Any of these three pharmaceutical titans could move the needle in your portfolio. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Pfizer’s BRAFTOVI BREAKWATER Trial Delivers Landmark Survival Gains in Colorectal Cancer
NEW YORK — Pfizer Inc. (NYSE: PFE) has announced breakthrough results from its Phase 3 BREAKWATER clinical trial, demonstrating that its BRAFTOVI (encorafenib) regimen significantly improves both... 
Via MarketMinute
News headline image
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗
Ozempic's rival is generating blockbuster revenue and gaining market share. 
Via The Motley Fool
News headline image
Nasdaq, S&P 500 Futures Edge Higher, Trump Speech In Focus: Why WMT, META, IBRX, MSFT, EBAY Are On Traders' Radar Today ↗
Data from Stocktwits indicated retail sentiment towards SPY and QQQ cooled to neutral. 
Via Stocktwits
Topics ETFs Economy Government
News headline image
2 High-Flying Stocks on Our Buy List and 1 Facing Challenges
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lofty expectations make them particularly... 
Via StockStory
Topics Firearms
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.